Luteal phase estradiol versus luteal phase GnRH antagonist administration: their effects on antral follicular size coordination and basal hormonal levels.

Rashidi B, Nasiri R, Rahmanpour H, Shahrokh Tehraninejad E, Deldar M

Iranian journal of reproductive medicine1 Jan 2011Cited by 1 (Europe PMC)

PMID26396582PMCIDPMC4576434PepBankPUB-26396582

Summary

BackgroundThe differential efficacy between long GnRH agonist with antagonist can partly be due to the preexisting differences in the early antral follicles before ovarian stimulation.ObjectiveTo compare the effect of pretreatment by estradiol with GnRH antagonist on antral follicular size coordination and basal hormone levels in GNRH antagonist protocol.Materials and methodsOn cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol. Participants were re-evaluated as on control/day 3.ResultsThere was a significant reduction of mean follicular sizes in each group after medical intervention (7.63±2.11 Vs. 4.30±0.92 in group A and 8.73±1.96 Vs. 4.13±1.11 in group B) (p=0.0001). The magnitude of follicular size reduction was significantly higher in group B (-4.60±2.04 Vs. -3.33±2.28) (0.027). There was a non significant attenuation of follicular size discrepancies in two groups. FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.ConclusionBoth luteal E2 and premenstrual GnRH antagonist administration reduces the follicular sizes significantly and GnRH antagonist acts more potently than E2 in this way but attenuation of follicular size discrepancies in both treatment is not significant.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women before an antagonist protocol, cetrorelix reduced follicular size more than estradiol.
In plain wordsIn women before an antagonist protocol, cetrorelix reduced follicular size more than estradiol.
Peptide
Cetrorelix
Outcome
DecreaseMean follicular size
Study
n = 30
Comparator
Oral estradiol 4mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Measurements
Follicular size reduction
−4.6 not stated
Group B (cetrorelix)
Reported variability
2.04 not stated
Group B reduction
Follicular size reduction
−3.33 not stated
Group A (estradiol)
Reported variability
2.28 not stated
Group A reduction
Source sentences
Summary
The magnitude of follicular size reduction was significantly higher in group B (-4.60±2.04 Vs. -3.33±2.28) (0.027).
3 context sentences(design, population, supporting numbers)
Summary · context
Both luteal E2 and premenstrual GnRH antagonist administration reduces the follicular sizes significantly and GnRH antagonist acts more potently than E2 in this way but attenuation of follicular size discrepancies in both treatment is not significant.
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658201
02HumanRandomized controlled trialEfficacy outcome
In women, FSH levels after cetrorelix pretreatment did not differ significantly from levels after estradiol pretreatment.
In plain wordsIn women, FSH levels after cetrorelix pretreatment did not differ significantly from levels after estradiol pretreatment.
Peptide
Cetrorelix
Outcome
No significant changeFSH levels
Study
n = 30
Comparator
Oral estradiol 4mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Source sentences
Summary
FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658206
03HumanRandomized controlled trialEfficacy outcome
In women, inhibin B levels after cetrorelix pretreatment did not differ significantly from levels after estradiol pretreatment.
In plain wordsIn women, inhibin B levels after cetrorelix pretreatment did not differ significantly from levels after estradiol pretreatment.
Peptide
Cetrorelix
Outcome
No significant changeInhibin B levels
Study
n = 30
Comparator
Oral estradiol 4mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Source sentences
Summary
FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658207
04HumanNon-randomized trialEfficacy outcome
In women before an antagonist protocol, mean follicular size decreased significantly after cetrorelix pretreatment, as in the estradiol group.
In plain wordsIn women, follicular size decreased after cetrorelix pretreatment compared with baseline, as in the estradiol group.
Peptide
Cetrorelix
Outcome
DecreaseMean follicular size
Study
n = 15
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Measurements
Mean follicular size
8.73 not stated
Group B before (cetrorelix)
Reported variability
1.96 not stated
Group B before
Mean follicular size
4.13 not stated
Group B after
Reported variability
1.11 not stated
Group B after
Source sentences
Summary
There was a significant reduction of mean follicular sizes in each group after medical intervention (7.63±2.11 Vs. 4.30±0.92 in group A and 8.73±1.96 Vs. 4.13±1.11 in group B) (p=0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658202
05HumanNon-randomized trialEfficacy outcome
In women before an antagonist protocol, follicular size discrepancies did not decrease significantly after cetrorelix, as in the estradiol group.
In plain wordsIn women, follicular size discrepancies did not decrease significantly after cetrorelix compared with baseline, as in the estradiol group.
Peptide
Cetrorelix
Outcome
No significant changeFollicular size discrepancies
Study
n = 15
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Source sentences
Summary
There was a non significant attenuation of follicular size discrepancies in two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658203
06HumanNon-randomized trialEfficacy outcome
In women, FSH levels decreased significantly after cetrorelix pretreatment, as in the estradiol group.
In plain wordsIn women, FSH levels decreased after cetrorelix pretreatment compared with baseline, as in the estradiol group.
Peptide
Cetrorelix
Outcome
DecreaseFSH levels
Study
n = 15
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Source sentences
Summary
FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658204
07HumanNon-randomized trialEfficacy outcome
In women, inhibin B levels decreased significantly after cetrorelix pretreatment, as in the estradiol group.
In plain wordsIn women, inhibin B levels decreased after cetrorelix pretreatment compared with baseline, as in the estradiol group.
Peptide
Cetrorelix
Outcome
DecreaseInhibin B levels
Study
n = 15
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3mg cetrorelix acetateAs given in this study (human).
Source sentences
Summary
FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol.
Summary · context
Participants were re-evaluated as on control/day 3.
Show in the study text Report a problemFND-2639658205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.